Cooperative Agreement UH3CA140233

This $731,451 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to model and understand the pathways of early growth dysregulation at the gastroesophageal junction (GEJ) cardia. The research aims to generate GEJ-cardia-derived organoid models using CRISPR-Cas9 genome editing to study the cellular biology and lipidomic profiles of early...

This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $678,399 to the University of Texas MD Anderson Cancer Center to conduct a prebiotic diet intervention study in metastatic melanoma patients receiving immune checkpoint inhibitor (ICI) therapy. The key objectives are to evaluate the effects of a prebiotic food-enriched diet (PREFED) on the gut microbiome, host metabolome, and immune response to...

This $467,659 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CFDA 93.847 "Diabetes, Digestive, and Kidney Diseases Extramural Research" program, supports research by The Trustees of the University of Pennsylvania to investigate the molecular and genetic drivers underlying the transition from non-dysplastic to dysplastic Barrett's esophagus. The study will leverage single-cell RNA sequencing, mitochondrial mutation-based lineage...

The National Cancer Institute (NCI) awarded a $398,738 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Pre-Cancer Diagnosis, LLC to develop a highly sensitive DNA hypermethylation-based diagnostic kit to identify Barrett's Esophagus (BE) patients at high risk of progressing to esophageal adenocarcinoma (EAC). The project aims to validate a panel of hypermethylated genes that can accurately distinguish between high-risk and low-risk BE patients, allowing...

This Project Grant award, totaling $622,003.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The goal of the project is to investigate the role of pathogenic germline mutations in Barrett's esophagus progression to esophageal adenocarcinoma, one of the most lethal cancers. Specifically, the project aims to: 1) Provide precise risk estimates of germline...

This federal Project Grant award of $426,425.00, funded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports a pilot study to investigate the role of gut microbiome alterations in the progression from metabolic dysfunction-associated steatotic liver disease (MASLD) to hepatocellular carcinoma (HCC). The key research objectives are to: 1) characterize baseline gut microbiome diversity in MASLD patients with and without HCC; 2) correlate changes in gut...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) provides funding of $716,314 to The Trustees of Columbia University in the City of New York to develop innovative therapeutics targeting FGFR2 alterations in gastroesophageal cancer. The key products and services to be delivered under this grant include: Utilizing novel mouse models of FGFR2-altered gastroesophageal cancer to develop and test highly effective FGFR2 biparatopic antibodies...

This $2,166,750 project grant from the National Institutes of Health's National Institute of Environmental Health Sciences will fund research into the role of the gut microbiome in host adaptation to environmental xenobiotics. The University of California, Berkeley will explore how exposure to commonly used pesticides shapes the gut microbiome of the model organism C. elegans, and the long-term health consequences for the host. Researchers will characterize microbiome-assisted adaptation to...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $300,000 to expand the Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort study at the University of California, Davis (UC Davis). The goal is to enroll approximately 1,000 participants with liver cirrhosis, with a focus on the Latinx population, and follow them prospectively to investigate the role of the gut-liver axis in hepatocellular...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $984,000 Cooperative Agreement (U01DK140936) to the University of Chicago to conduct a cross-sectional and longitudinal study of gut microbiota in Parkinson's disease (PD). The study aims to gain a better understanding of the role of gut dysbiosis in the development, progression, and prognosis of PD, which could lead to the identification of microbiome-based predictive biomarkers and the development of gut...